Position Statement on the Use of Bone Turnover Markers for Osteoporosis Treatment

키워드

참고문헌 (70)

1. Peck WA, "Consensus development conference: diagnosis, prophylaxis, and treatment of osteoporosis", Am J Med, 94, pp.646~650 (1993)
2. Weinstein RS, "True strength", J Bone Miner Res, 15, pp.621~625 (2000)
3. Blake GM, "Role of dual-energy X-ray absorptiometry in the diagnosis and treatment of osteoporosis", J Clin Densitom, 10, pp.102~110 (2007)
4. Feng X, "Disorders of bone remodeling", Annu Rev Pathol, 6, pp.121~145 (2011)
5. Garnero P, "Markers of bone resorption predict hip fracture in elderly women: the EPIDOS Prospective Study", J Bone Miner Res, 11, pp.1531~1538 (1996)
6. Garnero P, "Biochemical markers of bone turnover, endogenous hormones and the risk of fractures in postmenopausal women: the OFELY study", J Bone Miner Res, 15, pp.1526~1536 (2000)
7. Ross PD, "Serum bone alkaline phosphatase and calcaneus bone density predict fractures: a prospective study", Osteoporos Int, 11, pp.76~82 (2000)
8. Cosman F, "Clinician’s guide to prevention and treatment of osteoporosis", Osteoporos Int, 25, pp.2359~2381 (2014)
9. Orimo H, "Japanese 2011 guidelines for prevention and treatment of osteoporosis--executive summary", Arch Osteoporos, 7, pp.3~20 (2012)
10. Vasikaran S, "Markers of bone turnover for the prediction of fracture risk and monitoring of osteoporosis treatment: a need for international reference standards", Osteoporos Int, 22, pp.391~420 (2011)
11. 박소영, "Clinical Application of Bone Turnover Markers in Osteoporosis in Korea", 대한골대사학회지, 26(1), pp.19~24 (2019), 대한골대사학회
12. Nishizawa Y, "Guidelines for the use of bone metabolic markers in the diagnosis and treatment of osteoporosis (2012 edition)", J Bone Miner Metab, 31, pp.1~15 (2013)
13. Szulc P, "The role of bone turnover markers in monitoring treatment in postmenopausal osteoporosis", Clin Biochem, 45, pp.907~919 (2012)
14. Szulc P, "Use of CTX-I and PINP as bone turnover markers: National Bone Health Alliance recommendations to standardize sample handling and patient preparation to reduce pre-analytical variability", Osteoporos Int, 28, pp.2541~2556 (2017)
15. Christgau S, "Clinical evaluation of the Serum CrossLaps One Step ELISA, a new assay measuring the serum concentration of bone-derived degradation products of type I collagen C-telopeptides", Clin Chem, 44, pp.2290~2300 (1998)
16. Garnero P, "Evaluation of a fully automated serum assay for C-terminal cross-linking telopeptide of type I collagen in osteoporosis", Clin Chem, 47, pp.694~702 (2001)
17. Morovat A, "IDS iSYS automated intact procollagen-1-N-terminus pro-peptide assay: method evaluation and reference intervals in adults and children", Clin Chem Lab Med, 51, pp.2009~2018 (2013)
18. Qvist P, "Circadian variation in the serum concentration of C-terminal telopeptide of type I collagen (serum CTx): effects of gender, age, menopausal status, posture, daylight, serum cortisol, and fasting", Bone, 31, pp.57~61 (2002)
19. Redmond J, "Diurnal rhythms of bone turnover markers in three ethnic groups", J Clin Endocrinol Metab, 101, pp.3222~3230 (2016)
20. Clowes JA, "Effect of feeding on bone turnover markers and its impact on biological variability of measurements", Bone, 30, pp.886~890 (2002)
21. Gass ML, "Bone turnover marker profile in relation to the menstrual cycle of premenopausal healthy women", Menopause, 15, pp.667~675 (2008)
22. Bhattoa HP, "Prevalence and seasonal variation of hypovitaminosis D and its relationship to bone metabolism in healthy Hungarian men over 50 years of age: the HunMen Study", Osteoporos Int, 24, pp.179~186 (2013)
23. Pasco JA, "Seasonal periodicity of serum vitamin D and parathyroid hormone, bone resorption, and fractures: the Geelong Osteoporosis Study", J Bone Miner Res, 19, pp.752~758 (2004)
24. Weiler R, "Changes in bone turnover markers during the close season in elite football (soccer) players", J Sci Med Sport, 15, pp.255~258 (2012)
25. Bae SJ, "Efficacy of intravenously administered ibandronate in postmenopausal Korean women with insufficient response to orally administered bisphosphonates", J Bone Miner Metab, 30, pp.588~595 (2012)
26. Johnell O, "Biochemical indices of bone turnover and the assessment of fracture probability", Osteoporos Int, 13, pp.523~526 (2002)
27. Vergnaud P, "Undercarboxylated osteocalcin measured with a specific immunoassay predicts hip fracture in elderly women: the EPIDOS Study", J Clin Endocrinol Metab, 82, pp.719~724 (1997)
28. Garnero P, "Type I collagen racemization and isomerization and the risk of fracture in postmenopausal women: the OFELY prospective study", J Bone Miner Res, 17, pp.826~833 (2002)
29. Gerdhem P, "Biochemical markers of bone metabolism and prediction of fracture in elderly women", J Bone Miner Res, 19, pp.386~393 (2004)
30. Marques EA, "Association of bone turnover markers with volumetric bone loss, periosteal apposition, and fracture risk in older men and women: the AGES-Reykjavik longitudinal study", Osteoporos Int, 27, pp.3485~3494 (2016)
31. Melton LJ 3rd, "Relative contributions of bone density, bone turnover, and clinical risk factors to long-term fracture prediction", J Bone Miner Res, 18, pp.312~318 (2003)
32. Leiper JM, "A comparison of biosynthetic human insulin with porcine insulin in the blood glucose control of diabetic pregnancy", Diabet Med, 3, pp.49~51 (1986)
33. Ulivieri FM, "The role of carboxy-terminal cross-linking telopeptide of type I collagen, dual x-ray absorptiometry bone strain and Romberg test in a new osteoporotic fracture risk evaluation: A proposal from an observational study", PLoS One, 13, pp.e0190477~ (2018)
34. Vasikaran S, "Assessment of bone turnover in osteoporosis: harmonization of the total testing process", Clin Chem Lab Med, 56, pp.1603~1607 (2018)
35. Naylor KE, "Response of bone turnover markers to three oral bisphosphonate therapies in postmenopausal osteoporosis: the TRIO study", Osteoporos Int, 27, pp.21~31 (2016)
36. Black DM, "The effect of 6 versus 9 years of zoledronic acid treatment in osteoporosis: a randomized second extension to the HORIZON-Pivotal Fracture Trial (PFT)", J Bone Miner Res, 30, pp.934~944 (2015)
37. Miller PD, "Denosumab or zoledronic acid in postmenopausal women with osteoporosis previously treated with oral bisphosphonates", J Clin Endocrinol Metab, 101, pp.3163~3170 (2016)
38. Bone HG, "10 years of denosumab treatment in postmenopausal women with osteoporosis: results from the phase 3 randomised FREEDOM trial and open-label extension", Lancet Diabetes Endocrinol, 5, pp.513~523 (2017)
39. Lamy O, "Severe rebound-associated vertebral fractures after denosumab discontinuation: 9 clinical cases report", Clin Endocrinol Metab, 102, pp.354~358 (2017)
40. Naylor KE, "Response of bone turnover markers to raloxifene treatment in postmenopausal women with osteopenia", Osteoporos Int, 27, pp.2585~2592 (2016)
41. Finkelstein JS, "Effects of teriparatide, alendronate, or both on bone turnover in osteoporotic men", J Clin Endocrinol Metab, 91, pp.2882~2887 (2006)
42. Glover SJ, "Rapid and robust response of biochemical markers of bone formation to teriparatide therapy", Bone, 45, pp.1053~1058 (2009)
43. Eastell R, "Development of an algorithm for using PINP to monitor treatment of patients with teriparatide", Curr Med Res Opin, 22, pp.61~66 (2006)
44. Shirley M, "Abaloparatide: First global approval", Drugs, 77, pp.1363~1368 (2017)
45. Miller PD, "Effect of Abaloparatide vs placebo on new vertebral fractures in postmenopausal women with osteoporosis: A randomized clinical trial", JAMA, 316, pp.722~733 (2016)
46. McClung MR, "Romosozumab in postmenopausal women with low bone mineral density", N Engl J Med, 370, pp.412~420 (2014)
47. Delmas PD, "Effect of monitoring bone turnover markers on persistence with risedronate treatment of postmenopausal osteoporosis", J Clin Endocrinol Metab, 92, pp.1296~1304 (2007)
48. Diez-Perez A, "International osteoporosis foundation and European calcified tissue society working group. Recommendations for the screening of adherence to oral bisphosphonates", Osteoporos Int, 28, pp.767~774 (2017)
49. Sun V, "Improving family caregiver and patient outcomes in lung cancer surgery: Study protocol for a randomized trial of the multimedia self-management (MSM) intervention", Contemp Clin Trials, 83, pp.88~96 (2019)
50. Bindon B, "Osteoporotic fractures during bisphosphonate drug holiday", Endocr Pract, 24, pp.163~169 (2018)
51. Roberts J, "Changes in bone mineral density and bone turnover in patients on ‘drug holiday’ following bisphosphonate therapy: real-life clinic setting", Clin Endocrinol (Oxf), 84, pp.509~515 (2016)
52. McClung M, "Bisphosphonate therapy for osteoporosis: benefits, risks, and drug holiday", Am J Med, 126, pp.13~20 (2013)
53. Bonnick SL, "Monitoring osteoporosis therapy: bone mineral density, bone turnover markers, or both?", Am J Med, 119, pp.25~31 (2006)
54. Wasnich RD, "Antifracture efficacy of antiresorptive agents are related to changes in bone density", J Clin Endocrinol Metab, 85, pp.231~236 (2000)
55. Cummings SR, "Improvement in spine bone density and reduction in risk of vertebral fractures during treatment with antiresorptive drugs", Am J Med, 112, pp.281~289 (2002)
56. Camacho PM, "American association of clinical endocrinologists and American college of endocrinology clinical practice guidelines for the diagnosis and treatment of postmenopausal osteoporosis - 2016", Endocr Pract, 22, pp.1~42 (2016)
57. 이승헌, "Position Statement: Drug Holiday in Osteoporosis Treatment with Bisphosphonates in South Korea", 대한골대사학회지, 22(4), pp.167~174 (2015), 대한골대사학회
58. Anagnostis P, "Bisphosphonate drug holidays-when, why and for how long", Climacteric, 18(Suppl 2), pp.32~38 (2015)
59. Peisker A, "Cross-sectional study of four serological bone turnover markers for the risk assessment of medication-related osteonecrosis of the jaw", J Craniofac Surg, 29, pp.e137~e140 (2018)
60. Giusti A, "Atypical fractures of the femur and bisphosphonate therapy: A systematic review of case", case series studies, 2010, pp.47, 169~180
61. Friedlander AH, "High C-terminal cross-linking telopeptide levels are associated with a minimal risk of osteonecrosis of the jaws in patients taking oral bisphosphonates and having exodontia", J Oral Maxillofac Surg, 73, pp.1735~1740 (2015)
62. Lee JJ, "Factors predicting the prognosis of oral alendronate-related osteonecrosis of the jaws: a 4-year cohort study", Head Neck, 35, pp.1787~1795 (2013)
63. Lee CY, "CTX biochemical marker of bone metabolism. Is it a reliable predictor of bisphosphonate-associated osteonecrosis of the jaws after surgery? Part II: a prospective clinical study", Implant Dent, 19, pp.29~38 (2010)
64. Lee CY, "CTX biochemical marker of bone metabolism. Is it a reliable predictor of bisphosphonate-associated osteonecrosis of the jaws after surgery? Part I: biological concepts with a review of the literature", Implant Dent, 18, pp.492~500 (2009)
65. Iizuka Y, "Bone turnover markers and the factors associated with atypical femur fractures among Japanese patients", Injury, 47, pp.2484~2489 (2016)
66. Chiang C, "The use of bone turnover markers in chronic kidney disease-mineral and bone disorders", Nephrology (Carlton), 22(Suppl 2), pp.11~13 (2017)
67. Ueda M, "Clinical usefulness of the serum N-terminal propeptide of type I collagen as a marker of bone formation in hemodialysis patients", Am J Kidney Dis, 40, pp.802~809 (2002)
68. Cavalier E, "Variability of new bone mineral metabolism markers in patients treated with maintenance hemodialysis: implications for clinical decision making", Am J Kidney Dis, 61, pp.847~848 (2013)
69. Isakova T, "KDOQI US commentary on the 2017 KDIGO clinical practice guideline update for the diagnosis, evaluation, prevention, and treatment of chronic kidney disease-mineral and bone disorder (CKD-MBD)", Am J Kidney Dis, 70, pp.737~751 (2017)
70. Delanaye P, "Can we use circulating biomarkers to monitor bone turnover in CKD haemodialysis patients? Hypotheses and facts", Nephrol Dial Transplant, 29, pp.997~1004 (2014)

관련 논문AI추천